Glutamine synthetase and hepatocellular carcinoma

Area of Science:

• Biochemistry
• Oncology
• Hepatology

Background:

• Glutamine synthetase (GS) is crucial for glutamine synthesis in liver, kidney, and brain tissues.
• GS is implicated in abnormal liver lipid metabolism, inflammation, and serves as a risk factor for hepatocellular carcinoma (HCC).

Purpose of the Study:

• To explore the role of Glutamine Synthetase (GS) in the development and progression of hepatocellular carcinoma (HCC).
• To review the diagnostic and prognostic value of GS in HCC and its potential as a therapeutic target.

Main Methods:

• Literature review on Glutamine Synthetase (GS) function in liver physiology and pathology.
• Analysis of GS involvement in signaling pathways (mTOR, Wnt/β-catenin) relevant to HCC.
• Evaluation of GS as a biomarker and therapeutic target in HCC.

Main Results:

• GS contributes to liver inflammation and is linked to HCC development through various pathways.
• Combined biomarkers (HSP70, GPC3, GS) enhance HCC diagnostic accuracy.
• GS expression influences HCC cell sensitivity to therapies, including radiotherapy, chemotherapy, and immunotherapy.

Conclusions:

• Glutamine synthetase (GS) is a significant factor in HCC pathogenesis and progression.
• GS holds potential as a diagnostic marker and therapeutic target for hepatocellular carcinoma.
• Further research into GS modulation could lead to novel HCC treatment strategies.